<?xml version="1.0" encoding="UTF-8"?>
<p>Next, we wondered whether vaccines based on a VSV vector similarly depend on 
 <italic>Usp18</italic>. VSV-EBOV (Ervebo) is a powerful vaccine against the Ebola virus, which was engineered on the backbone of a WT VSV and the Glycoprotein of the Ebola Zaire virus. To get insights into the early immune events of VSV-EBOV administration, we infected mice systemically with VSV-EBOV. Seven hours after infection, WT mice showed enhanced viral titers in dLN compared to the 
 <italic>CD169</italic>-Cre
 <sup>+/
  <italic>ki</italic>
 </sup> x 
 <italic>Usp18</italic>
 <sup>fl/fl</sup> mice (
 <xref ref-type="fig" rid="vaccines-08-00142-f003">Figure 3</xref>A). As viral titers in the spleen were below the detection limit, we performed a qRT-PCR analysis to quantify VSV-EBOV NP expression in the spleen and lymph nodes, which was strongly reduced in the 
 <italic>CD169</italic>-Cre
 <sup>+/
  <italic>ki</italic>
 </sup> x 
 <italic>Usp18</italic>
 <sup>fl/fl</sup> mice (
 <xref ref-type="fig" rid="vaccines-08-00142-f003">Figure 3</xref>B). VSV-EBOV was detected in the spleens of WT mice, but hardly in the spleen of 
 <italic>CD169</italic>-Cre
 <sup>+/
  <italic>ki</italic>
 </sup> x 
 <italic>Usp18</italic>
 <sup>fl/fl</sup> mice (
 <xref ref-type="fig" rid="vaccines-08-00142-f003">Figure 3</xref>C).
</p>
